Efficacy News and Research

RSS
Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Positive results from Phase IIa clinical study of LIPO-102

Positive results from Phase IIa clinical study of LIPO-102

New breakthrough: Seaweed for treatment of swine flu

New breakthrough: Seaweed for treatment of swine flu

Cadence Pharmaceuticals resubmits OFIRMEV NDA

Cadence Pharmaceuticals resubmits OFIRMEV NDA

Six abstracts featuring FORE-SIGHT system presented at Pediatric Academic Societies meeting

Six abstracts featuring FORE-SIGHT system presented at Pediatric Academic Societies meeting

Pay-for-performance may create unintended financial incentives for doctors to discriminate against obese patients

Pay-for-performance may create unintended financial incentives for doctors to discriminate against obese patients

WHO announces new guidelines for production, regulation and control of snake antivenoms

WHO announces new guidelines for production, regulation and control of snake antivenoms

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Additional pivotal Phase 3 trial data for MoxDuo IR released

Additional pivotal Phase 3 trial data for MoxDuo IR released

Study: Flaxseed diet reduces ovarian cancer, increases survival rates

Study: Flaxseed diet reduces ovarian cancer, increases survival rates

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

BELLUS Health to discontinue NC-503 diabetes development program

BELLUS Health to discontinue NC-503 diabetes development program

Derma Sciences adds XTRASORB Foam dressing to advanced wound care product portfolio

Derma Sciences adds XTRASORB Foam dressing to advanced wound care product portfolio

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.